Anemia Clinical Trial
Official title:
A Phase 1/2 Open-Label, Multicenter Study of INCB000928 Administered as a Monotherapy or in Combination With Ruxolitinib in Participants With Anemia Due to Myeloproliferative Disorders
This Phase 1/2, open-label, dose-finding study is intended to evaluate the safety and tolerability, PK, PD, and efficacy of INCB000928 administered as monotherapy or in combination with ruxolitinib in participants with MF who are transfusion-dependent or presenting with symptomatic anemia. This study will consist of 2 parts: dose escalation and expansion.
Status | Recruiting |
Enrollment | 206 |
Est. completion date | June 30, 2026 |
Est. primary completion date | November 28, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Participants with MF who are transfusion-dependent or present with symptomatic anemia, defined as follows: 1. Anemia: An Hgb value < 10 g/dL demonstrated during screening recorded on 3 separate occasions with at least 7 days between measurements (Note: RBC transfusion must be at least 2 weeks before the Hgb measurement during screening). 2. Transfusion-dependent: Participant has received at least 4 units of RBC transfusions during the 28 days immediately preceding Cycle 1 Day 1 OR has received an average of at least 4 units of RBC transfusions in the 8 weeks immediately preceding Cycle 1 Day 1, for an Hgb level of < 8.5 g/dL, in the absence of bleeding or treatment-induced anemia. In addition, the most recent transfusion episode must have occurred in the 28 days before Cycle 1 Day 1. - ECOG performance status score of the following: 1. 0 or 1 for the dose-escalation stages. 2. 0, 1, or 2 for the dose-expansion stage. - Life expectancy is greater than 6 months - Agreement to avoid pregnancy or fathering children. - Ineligible to receive or have not responded to available therapies for anemia such as ESAs. - For TGA: - Participants previously treated with JAK inhibitors for at least 12 weeks. - Participants with intermediate-2 or high DIPSS MF according to IWG-MRT criteria. - For TGB: - Participants must have been on a therapeutic and stable regimen of ruxolitinib for at least 12 consecutive weeks immediately preceding the first dose of study treatment. - Participants with intermediate-1, intermediate-2, or high DIPSS MF according to IWG-MRT criteria. - For TGC: - Participants must be JAK inhibitor treatment naive (no prior treatment with any JAK inhibitor) and have an indication for initiation of ruxolitinib treatment. - Participants with intermediate-1, intermediate-2, or high DIPSS MF according to IWG-MRT criteria. Exclusion Criteria: - Undergone any prior allogenic or autologous stem cell transplantation or a candidate for such transplantation. - Any prior chemotherapy, immunomodulatory drug therapy, immunosuppressive therapy, biological therapy, endocrine therapy, targeted therapy, antibody or hypomethylating agent to treat the participant's disease, with the exception of ruxolitinib for TGB only, within 5 half-lives or 28 days (whichever is shorter) before the first dose of study treatment. - Laboratory Values outside of protocol defined range at screening. |
Country | Name | City | State |
---|---|---|---|
Canada | McGill University Jewish General Hospital | Montreal | Quebec |
Canada | Princess Margaret Cancer Center | Toronto | Ontario |
France | Centre Hospitalier D'Angers | Angers Cedex 01 | |
France | Institut Paoli Calmettes | Marseille Cedex 9 | |
France | Hospital Saint Louis | Paris | |
Italy | Azienda Ospedaliera Papa Giovanni Xxiii | Bergamo | |
Italy | S Orsolas University Hospital Seragnoli Institute of Hematology | Bologna | |
Italy | Azienda Ospedaliero-Universitaria Careggi (Aouc) | Firenze | |
Italy | Azienda Ospedaliera Universitaria San Luigi Gonzaga Orbassano | Orbassano | |
Italy | Comitato Di Bioetica Della Fondazione Irccs Policlinico San Matteo | Pavia | |
Italy | Ospedale Santa Maria Della Misericordia Perugia | Perugia | |
Japan | Tokyo Medical and Dental University Hospital | Bunkyo-ku | |
Japan | Chiba Cancer Center | Chiba | |
Japan | Gifu Municipal Hospital | Gifu | |
Japan | Kansai Medical University Hospital | Hirakata | |
Japan | Kumamoto Shinto General Hospital | Kumamoto | |
Japan | Osaka International Cancer Institute | Osaka-shi | |
United Kingdom | United Lincolnshire Hospitals | Boston | |
United Kingdom | University Hospital of Wales | Cardiff | WLS |
United Kingdom | Lincoln County Hospital | Lincoln | |
United Kingdom | Royal Cornwall Hospital Truro Sunrise Centre | Truro | |
United States | Emory University - Winship Cancer Institute | Atlanta | Georgia |
United States | Emory University-Winship Cancer Institute | Atlanta | Georgia |
United States | City of Hope National Medical Center | Duarte | California |
United States | Duke University Medical Center, Department of Hematologic Malignancies and Cellular Therapy | Durham | North Carolina |
United States | Start Midwest | Grand Rapids | Michigan |
United States | Md Anderson Cancer Center | Houston | Texas |
United States | City of Hope Orange County | Irvine | California |
United States | Usc Norris Comprehensive Cancer Center | Los Angeles | California |
United States | Vanderbilt University Medical Center | Nashville | Tennessee |
United States | Weill Cornell Medical Centers | New York | New York |
United States | Stanford Cancer Center | Palo Alto | California |
United States | Washington University School of Medicine | Saint Louis | Missouri |
United States | Prebys Cancer Center | San Diego | California |
Lead Sponsor | Collaborator |
---|---|
Incyte Corporation |
United States, Canada, France, Italy, Japan, United Kingdom,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Number of treatment-related adverse events | To determine the safety and tolerability of INCB000928 administered as monotherapy (TGA) or in combination with ruxolitinib (TGB and TGC). | Approximately up to 13 months | |
Secondary | Anemia Response | Defined as an increase in hemoglobin. | Approximately up to 13 months | |
Secondary | Duration of Anemia Response | Duration of anemia response at baseline. | Approximately up to 13 months | |
Secondary | Mean Change of Hemoglobin | Mean change in hemoglobin levels from baseline. | Approximately up to 13 months | |
Secondary | Rate of RBC transfusion | Defined as the average number of RBC units. | Approximately up to 13 months | |
Secondary | TGB and TGC only -Splenic Volume | Defined as the proportion of participants achieving a targeted reduction in spleen volume. | Approximately up to 13 months | |
Secondary | TGB and TGC Only - Splenic Length | Defined as the proportion of participants achieving a targeted reduction in spleen length. | Approximately Up to 13 months | |
Secondary | TGB and TGC only - Objective Response Rate | Defined as the proportion of participants with Complete Response or Partial Response. | Approximately up to 13 months | |
Secondary | TGB and TGC only - Progression Free Survival | Defined as the interval from the first dose of study treatment until the first documented progression or death. | Approximately up to 13 months | |
Secondary | TGB and TGC only - Leukemia Free Survival | Defined as the interval from the first dose of study treatment until the first documented leukemia transformation or death from any cause. | Approximately upto 13 months | |
Secondary | AUC | Area Under the Plasma Concentration versus Time curve of INCB 00928-104. | Approximately up to 13 months | |
Secondary | Tmax | Time to reach maximum (peak) plasma concentration of INCB 00928-104. | Approximately up to 13 months | |
Secondary | AUC0-t | Area under the plasma concentration-time curve from time = 0 to the last measurable concentration at time = t. | Approximately up to 13 months | |
Secondary | Hepcidin levels | Effect of INCB000928 administered as monotherapy (TGA) or in combination with ruxolitinib (TGB and TGC) on hepcidin levels. | Approximately up to 13 months | |
Secondary | Iron Homeostasis | Effect of INCB000928 administered as monotherapy (TGA) or in combination with ruxolitinib (TGB and TGC) on iron homeostasis parameters such as TSI, ferritin, transferrin, TSAT, TIBC, UIBC, and serum NTBI. | Approximately up to 13 months | |
Secondary | Erythropoesis | Effect of INCB000928 administered as monotherapy (TGA) or in combination with ruxolitinib (TGB and TGC) on erythropoiesis parameters such as RC, NRBC, MCV, MCH, Hgb, Hct, RBC count, MCHC, and RDW. | Approximately up to 13 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT00801931 -
Double Cord Blood Transplant for Patients With Malignant and Non-malignant Disorders
|
Phase 1/Phase 2 | |
Completed |
NCT02948283 -
Metformin Hydrochloride and Ritonavir in Treating Patients With Relapsed or Refractory Multiple Myeloma or Chronic Lymphocytic Leukemia
|
Phase 1 | |
Completed |
NCT03341338 -
Genes-in-Action - Hepcidin Regulation of Iron Supplementation
|
||
Completed |
NCT00060398 -
Epoetin Alfa With or Without Dexamethasone in Treating Fatigue and Anemia in Patients With Hormone-Refractory Prostate Cancer
|
Phase 3 | |
Recruiting |
NCT05384691 -
Efficacy of Luspatercept in ESA-naive LR-MDS Patients With or Without Ring Sideroblasts Who do Not Require Transfusions
|
Phase 2 | |
Not yet recruiting |
NCT06309641 -
Methemoglobinemia Following Intravenous Iron Treatment
|
||
Completed |
NCT02912494 -
A Phase III Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02888171 -
Impact of Ferric Citrate vs Ferrous Sulfate on Iron Parameters and Hemoglobin in Individuals With CKD and Iron Deficiency
|
N/A | |
Completed |
NCT02912533 -
A Long-term Study of JR-131 in Renal Anemia Patients With Chronic Kidney Disease (CKD)
|
Phase 3 | |
Completed |
NCT02930850 -
Spot-Check Noninvasive Hemoglobin (SpHb) Clinical Validation
|
N/A | |
Completed |
NCT03822884 -
Pharmacokinetic/Pharmacodynamic Study of 3 Subcutaneous Single Dose Epoetin Alfa Formulations in Healthy Volunteers
|
Phase 1 | |
Completed |
NCT02603250 -
Evaluation of Hemoglobin Measurement Tools for Child Anemia Screening in Rwanda
|
N/A | |
Completed |
NCT02384122 -
Efficacy of Octreotide on Blood and Iron Requirements in Patients With Anemia Due to Angiodysplasias
|
Phase 3 | |
Completed |
NCT02176759 -
Iron Absorption From Rice Fortified With Ferric Pyrophosphate
|
N/A | |
Completed |
NCT01922479 -
Pilot Study of Ferric Carboxymaltose to Treat Iron Deficiency in Asians With Heart Failure
|
Phase 4 | |
Completed |
NCT02310113 -
Transfusion and Skeletal Muscle Tissue Oxygenation
|
N/A | |
Withdrawn |
NCT01934842 -
A Study to Compare Analyte Levels in Blood Collected Using an Investigational Collection Device With a Commercial Predicate
|
N/A | |
Completed |
NCT01693029 -
Study to Compare Safety and Efficacy of HX575 Epoetin Alfa and US-licensed Epoetin Alfa
|
Phase 3 | |
Completed |
NCT01432717 -
Study of ACE-536 in Healthy Postmenopausal Women
|
Phase 1 | |
Completed |
NCT01458028 -
Age and Gender Effects on the Pharmacokinetics of BAY85-3934
|
Phase 1 |